Geron (GERN) Total Liabilities (2010 - 2026)
Geron's (GERN) quarterly Total Liabilities came in at $300.4 million in Q2 2026, up 1.6% year-over-year from $295.7 million in Q2 2025, and down 1.51% quarter-over-quarter from $305.0 million in Q1 2026.
Analysis
Geron (GERN) Total Liabilities (2010 - 2026) Analysis & Trends
Geron has disclosed Total Liabilities across 17 years of filings, most recently posting $300.4 million for Q2 2026.
- In Q2 2026, Total Liabilities rose 1.6% year-over-year to $300.4 million; the TTM figure through Jun 2026 stood at $300.4 million (up 1.6% YoY), while the FY2025 annual figure was $344.7 million, up 9.96% from the prior year.
- Total Liabilities came in at $300.4 million for Q2 2026 at Geron, down from $305.0 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $344.7 million in Q4 2025 to a low of $96.1 million in Q2 2022.
- Average Total Liabilities over 5 years is $195.6 million, with a median of $144.4 million recorded in 2023.
- Year-over-year, Total Liabilities slipped 2.09% in 2023 and soared 114.51% in 2024.
- Over 5 years, Total Liabilities stood at $110.6 million in 2022, then soared by 32.15% to $146.1 million in 2023, then soared by 114.51% to $313.5 million in 2024, then increased by 9.96% to $344.7 million in 2025, then fell by 12.85% to $300.4 million in 2026.
- Per Business Quant data, the three most recent Total Liabilities figures were $300.4 million in Q2 2026, $305.0 million in Q1 2026, and $344.7 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 83.95 Bn |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | 37.53 Bn |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 7.18 Bn |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 10.02 Bn |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 1.62 Bn |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | 4.20 Bn |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 4.20 Bn |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 13.24 Bn |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | 384.62 Mn |
| 10 | Geron | 914.60 Mn | 613.75 Mn | - | 300.40 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 300.40 Mn |
| Mar 31, 2026 | 305.01 Mn |
| Dec 31, 2025 | 344.67 Mn |
| Sep 30, 2025 | 318.68 Mn |
| Jun 30, 2025 | 295.67 Mn |
| Mar 31, 2025 | 294.21 Mn |
| Dec 31, 2024 | 313.46 Mn |
| Sep 30, 2024 | 152.67 Mn |
| Jun 30, 2024 | 142.70 Mn |
| Mar 31, 2024 | 137.21 Mn |
| Dec 31, 2023 | 146.13 Mn |
| Sep 30, 2023 | 122.40 Mn |
| Jun 30, 2023 | 116.87 Mn |
| Mar 31, 2023 | 98.82 Mn |
| Dec 31, 2022 | 110.58 Mn |
| Sep 30, 2022 | 124.43 Mn |
| Jun 30, 2022 | 96.11 Mn |
| Mar 31, 2022 | 100.93 Mn |
| Dec 31, 2021 | 99.62 Mn |
| Sep 30, 2021 | 77.54 Mn |